Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in 
treatment of non-small cell lung cancer with the mTOR inhibitor everolimus

Nogova, Lucia; Boellaard, Ronald; Kobe, Carsten; Hoetjes, Nikie; Zander, Thomas; Gross, Stefan Hubert; Dimitrijevic, Sasa; Pellas, Theodore; Eschner, Wolfgang; Schmidt, Katja; Bangard, Christopher; Hayes, Wendy; Thomas, Roman K.; Dietlein, Markus; Giaccone, Giuseppe; Hoekstra, Otto S.; Lammertsma, Adriaan A.; Wolf, Juergen

doi:10.2967/jnumed.109.065367

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus

MPS-Authors

Nogova, Lucia
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Boellaard, Ronald
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Kobe, Carsten
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Hoetjes, Nikie
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

/persons/resource/persons147352

Zander, Thomas
Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Gross, Stefan Hubert
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Dimitrijevic, Sasa
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Pellas, Theodore
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Eschner, Wolfgang
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Schmidt, Katja
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Bangard, Christopher
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Hayes, Wendy
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

/persons/resource/persons147315

Thomas, Roman K.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147154

Dietlein, Markus
Translational Neurocircuitry, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Giaccone, Giuseppe
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Hoekstra, Otto S.
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Lammertsma, Adriaan A.
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

Wolf, Juergen
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Nogova, L., Boellaard, R., Kobe, C., Hoetjes, N., Zander, T., Gross, S. H., et al. (2009). Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. Journal of Nuclear Medicine, 50(11), 1815-1819. doi:10.2967/jnumed.109.065367.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0026-D425-2